ESTA · Establishment Labs Holdings Inc.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2026. Second Quarter Highlights and Outlook (Unaudited) Revenue of $67.5 million, up 31.7% from Q2 2025, and sequential growth of 12.8% from Q1 2026 $24.7 million of sales in the United States, up 26% from Q1 2026 Guidance raised to $269 million to $271 million, an increase from previous guidance of $266.5 million to $268.5 million Minimally invasive revenue of $12.1 million for the quarter Gross margin of 70.6% compared to 68.8% in the year-ago period Loss from operations was $4.3 million compared to a loss of $14.1 million in the year-ago period Adjusted EBITDA income of $3.7 million compared to a loss of $8.5 million in the year-ago period Cash balance of $71.2 million as of June 30, 2026, a $16.5 million improvement from

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2026, before the market opens on Thursday, August 6, 2026, and will host a conference call at 8:30 AM ET that day to discuss those results. To participate in the conference call, Dial: (+1) 888-396-8049 (US & Canada) / (+1) 416-764-8646 (international). The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The company offers a portfolio of solutions for breast health, breast

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Taylor Harris to its Board of Directors. Mr. Harris brings more than 25 years of experience in corporate finance, executive leadership and board governance across healthcare, medical technology and life sciences companies. He currently serves on the board of directors of Procept BioRobotics and previously served as a director of Omada Health and Endologix. Most recently, he served as Chief Executive Officer of Cutera, Inc. Prior to Cutera, Mr. Harris served as Chief Financial Officer of MyoKardia, where he helped guide the company through its acquisition by Bristol Myers Squibb in a transaction valued at $13.1 billion. Earlier in his career, he served as Chief Financial Officer of Zeltiq Aesthetics through its acquisition by Allergan and as Chief Financial Officer

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, will be added as a member of the US small-cap Russell 2000 ® Index, effective when the US market opens on June 29 th as part of the 2026 Russell indexes reconstitution. Membership in the Russell 2000 ® Index, which remains in place for half a year beginning 2026, is based on membership in the broad-market Russell 3000 ® Index. The stock was also automatically added to the appropriate growth and value indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2025, about $12.2 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. For more information on the Russell 2000 ® Index and the

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2026. First Quarter Highlights and Outlook (Unaudited) Revenue of $59.9 million, up 44.7% from Q1 2025, with guidance raised to $266.5 million to $268.5 million $19.6 million of Motiva sales in the United States, up 13.3% from Q4 2025 Minimally invasive revenue of $9.1 million for the quarter Gross margin of 70.7% compared to 67.2% in the year-ago period Loss from operations was $6.5 million compared to a loss of $16.9 million in the year-ago period Adjusted EBITDA income of $1.2 million compared to a loss of $12.1 million in the year-ago period Cash use $7.5 million compared to use of $21.2 million in the year-ago period Cash balance of $68.1 million as of March 31, 2026 “Our momentum is accelerating across both the United

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into a $300 million senior secured term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The amended and restated facility refinances the company’s existing debt and allows access to additional capital to support ongoing operations and future strategic growth initiatives. “This strengthens our capital structure by extending our maturity and enhancing our financial flexibility,” said Sandra Harris, Chief Financial Officer of Establishment Labs. “The initial tranche fully refinances our existing debt until 2031 and the additional capacity provides flexibility to support future strategic initiatives. Our business continues to accelerate, and we expect to be positive free cash flow in the second half of this year with substantial growth

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2026, before the market opens on Wednesday, May 6, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, Dial: 877-407-8037 (US & Canada) +1 201-689-8037 (international). The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com . About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The company offers a portfolio of solutions for breast health, breast aesthetics, and

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to impro

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced a strategic leadership transition of Raj Denhoy, current Chief Financial Officer to Senior Vice President, Global Strategy, and the appointment of Cassandra “Sandra” Harris to Senior Vice President and Chief Financial Officer, effective March 9, 2026. “Over the past few years, we have been focused on driving efficient execution and scalability. With the company well positioned for its next chapter of growth, we are creating additional leadership capacity to maintain operational momentum while managing several initiatives that require strong leadership and oversight,” said Peter Caldini, Chief Executive Officer of Establishment Labs. “Raj’s move into a dedicated strategy role and Sandra’s appointment as CFO reflect our confidence in the strength and future of our business. These

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided 2026 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $64.6 million, an increase of 45.2% from the year-ago period. 2025 revenue of $211.1 million, an increase of 27.2% over 2024. Motiva U.S. revenue in the fourth quarter of $17.3 million, and full year U.S. revenue of $45.6 million. Fourth quarter net loss from operations of $3.9 million, a 79% reduction compared to a net loss of $18.7 million in the year-ago period. Fourth quarter adjusted EBITDA of positive $5.5 million, an $18.6 million increase compared to a loss of $13.1 million in the year-ago period. Cash balance of $75.6 million as of December 31, 2025, an increase of $4.9 million compared to Q3 2025. 2026

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in TD Cowen's 46th Annual Health Care Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Monday, March 2, 2026 at 9:10 a.m. ET. A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/ . Archived versions of the webcasts will be available on the same website following the completion of the events. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, February 24, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13758679. The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com . About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of

Revenue for the quarter ended December 31, 2025 is expected to be between $64.0 million and $65.0 million, including between $17.0 million and $17.5 million from Motiva sales in the United States. Revenue for fiscal year 2025 is expected to be in the range of $210.5 million to $211.5 million, representing growth of approximately 27% over 2024, including between $45.4 million and $45.9 million from Motiva sales in the United States. The Company’s year-end 2025 cash position is expected to be approximately $75.5 million, an increase of $4.8 million from the end of the third quarter of 2025. Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced preliminary unaudited financial results for the three months and fiscal year ended December 31, 2025. Establishment Labs’ preliminary unaudited revenue for the fourth quarter of 2025 is expected to